question_id stringlengths 33 41 | question stringlengths 87 312 | question_style stringclasses 3
values | guideline_id stringclasses 4
values | guideline_name stringclasses 4
values | source dict |
|---|---|---|---|---|---|
dyslipidemia-2026_sec-7-2_sdm_q01 | How should I explain to a patient with a family history of premature ASCVD the importance of a fasting lipid profile to accurately estimate their LDL-C levels? | sdm | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-2",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-2"
],
"title_path": [
"Evaluation and Diagnosis",
"Measurement of TC, LDL-C, HDL-C, TG, and Non–HDL-C"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-2",
"char_count": 9646
... |
dyslipidemia-2026_sec-7-3_lookup_q01 | What is the recommendation for measuring apoB in adults on lipid-lowering therapy with a history of ASCVD, CKM syndrome, type 2 diabetes, and/or elevated triglycerides once LDL-C and/or non-HDL-C goals are reached? | lookup | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-3",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-3"
],
"title_path": [
"Evaluation and Diagnosis",
"Measurement of ApoB"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-3",
"char_count": 6820
} |
dyslipidemia-2026_sec-7-3_scenario_q01 | A 50-year-old man without any history of cardiovascular disease or lipid-lowering therapy presents with a family history of hyperlipidemia. Is it advisable to measure his apoB levels to assess his risk for atherosclerotic cardiovascular disease? | scenario | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-3",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-3"
],
"title_path": [
"Evaluation and Diagnosis",
"Measurement of ApoB"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-3",
"char_count": 6820
} |
dyslipidemia-2026_sec-7-3_sdm_q01 | How can I explain the importance of measuring apoB to my patient with diabetes and high LDL, especially in terms of guiding their treatment options after reaching LDL-C goals? | sdm | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-3",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-3"
],
"title_path": [
"Evaluation and Diagnosis",
"Measurement of ApoB"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-3",
"char_count": 6820
} |
dyslipidemia-2026_sec-7-4_lookup_q01 | What is the recommendation for measuring Lp(a) concentration in all adults for ASCVD risk assessment? | lookup | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-4",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-4"
],
"title_path": [
"Evaluation and Diagnosis",
"Measurement of Lp(a)"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-4",
"char_count": 7602
} |
dyslipidemia-2026_sec-7-4_scenario_q01 | A 62-year-old woman with a family history of premature atherosclerotic cardiovascular disease (ASCVD) presents for a routine check-up. Should we measure her lipoprotein(a) levels to assess her ASCVD risk? | scenario | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-4",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-4"
],
"title_path": [
"Evaluation and Diagnosis",
"Measurement of Lp(a)"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-4",
"char_count": 7602
} |
dyslipidemia-2026_sec-7-4_sdm_q01 | How can I explain the importance of measuring Lp(a) levels to a patient with a family history of premature ASCVD, and what should I say to address any concerns they may have about the testing process? | sdm | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-4",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-4"
],
"title_path": [
"Evaluation and Diagnosis",
"Measurement of Lp(a)"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-4",
"char_count": 7602
} |
dyslipidemia-2026_sec-7-5_lookup_q01 | What is the recommended frequency for performing a lipid profile in individuals on lipid-lowering therapy after initiation or dose adjustment? | lookup | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-5",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-5"
],
"title_path": [
"Evaluation and Diagnosis",
"Monitoring and Follow-Up"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-5",
"char_count": 7842
} |
dyslipidemia-2026_sec-7-5_scenario_q01 | A 55-year-old man with severe hypercholesterolemia has just initiated lipid-lowering therapy. How soon after starting his medication should he have his first lipid profile done? | scenario | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-5",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-5"
],
"title_path": [
"Evaluation and Diagnosis",
"Monitoring and Follow-Up"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-5",
"char_count": 7842
} |
dyslipidemia-2026_sec-7-5_sdm_q01 | How can I effectively communicate to my patient the importance of regular lipid profile testing after starting lipid-lowering therapy, especially considering their previous adherence challenges? | sdm | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-7-5",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-7",
"sec-7-5"
],
"title_path": [
"Evaluation and Diagnosis",
"Monitoring and Follow-Up"
],
"chapter_id": "sec-7",
"subtopic_id": "sec-7-5",
"char_count": 7842
} |
dyslipidemia-2026_sec-8-1_lookup_q01 | What dietary patterns should be promoted in children and healthy adults to reduce the risk of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD)? | lookup | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-8-1",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-8",
"sec-8-1"
],
"title_path": [
"Management",
"Lifestyle Management"
],
"chapter_id": "sec-8",
"subtopic_id": "sec-8-1",
"char_count": 40549
} |
dyslipidemia-2026_sec-8-1_scenario_q01 | A 38-year-old woman recently diagnosed with dyslipidemia is concerned about her lipid levels. She is currently sedentary and has not engaged in regular exercise. What guidelines should be recommended for her physical activity to improve her cardiovascular health? | scenario | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-8-1",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-8",
"sec-8-1"
],
"title_path": [
"Management",
"Lifestyle Management"
],
"chapter_id": "sec-8",
"subtopic_id": "sec-8-1",
"char_count": 40549
} |
dyslipidemia-2026_sec-8-1_sdm_q01 | How can I effectively communicate the importance of a heart-healthy diet and lifestyle changes to a 45-year-old male patient with high LDL cholesterol who is skeptical about dietary modifications? | sdm | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-8-1",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-8",
"sec-8-1"
],
"title_path": [
"Management",
"Lifestyle Management"
],
"chapter_id": "sec-8",
"subtopic_id": "sec-8-1",
"char_count": 40549
} |
dyslipidemia-2026_sec-8-2_lookup_q01 | What is the recommended initial pharmacotherapy for adults with severe hypercholesterolemia (LDL-C ≥190 mg/dL) who do not have clinical ASCVD? | lookup | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-8-2",
"level": 3,
"section_type": "container",
"path": [
"bodymatter",
"sec-8",
"sec-8-2"
],
"title_path": [
"Management",
"Medical Management"
],
"chapter_id": "sec-8",
"subtopic_id": "sec-8-2",
"char_count": 390822
} |
dyslipidemia-2026_sec-8-2_scenario_q01 | A 35-year-old man presents with severe hypertriglyceridemia, with levels exceeding 1000 mg/dL, and a recent hospitalization for pancreatitis. What immediate actions should be taken to manage his triglyceride levels? | scenario | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-8-2",
"level": 3,
"section_type": "container",
"path": [
"bodymatter",
"sec-8",
"sec-8-2"
],
"title_path": [
"Management",
"Medical Management"
],
"chapter_id": "sec-8",
"subtopic_id": "sec-8-2",
"char_count": 390822
} |
dyslipidemia-2026_sec-8-2_sdm_q01 | How can I effectively discuss the potential benefits and risks of initiating statin therapy with a 70-year-old male patient who has a history of heart disease and is concerned about possible side effects? | sdm | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-8-2",
"level": 3,
"section_type": "container",
"path": [
"bodymatter",
"sec-8",
"sec-8-2"
],
"title_path": [
"Management",
"Medical Management"
],
"chapter_id": "sec-8",
"subtopic_id": "sec-8-2",
"char_count": 390822
} |
dyslipidemia-2026_sec-9-1_lookup_q01 | What is recommended for adults with dyslipidemia before starting lipid-lowering medication to enhance patient adherence? | lookup | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-9-1",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-9",
"sec-9-1"
],
"title_path": [
"Complications of Management",
"Medication Safety and Therapy-Associated Side Effects"
],
"chapter_id": "sec-9",
"subtopic_id": "sec-9-1",
"char_count":... |
dyslipidemia-2026_sec-9-1_scenario_q01 | A 62-year-old woman with a history of dyslipidemia and stable chronic liver disease is considering starting statin therapy. What does the guideline recommend for her regarding the initiation of lipid-lowering medication? | scenario | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-9-1",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-9",
"sec-9-1"
],
"title_path": [
"Complications of Management",
"Medication Safety and Therapy-Associated Side Effects"
],
"chapter_id": "sec-9",
"subtopic_id": "sec-9-1",
"char_count":... |
dyslipidemia-2026_sec-9-1_sdm_q01 | How can I effectively communicate the importance of discussing the risks and benefits of statin therapy with a patient who has dyslipidemia before starting treatment? | sdm | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-9-1",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-9",
"sec-9-1"
],
"title_path": [
"Complications of Management",
"Medication Safety and Therapy-Associated Side Effects"
],
"chapter_id": "sec-9",
"subtopic_id": "sec-9-1",
"char_count":... |
dyslipidemia-2026_sec-9-2_lookup_q01 | What is recommended for adults starting statin therapy regarding their other cardiovascular medications to reduce the risk of adverse events? | lookup | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-9-2",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-9",
"sec-9-2"
],
"title_path": [
"Complications of Management",
"Statin-Cardiovascular Drug Interactions"
],
"chapter_id": "sec-9",
"subtopic_id": "sec-9-2",
"char_count": 6790
} |
dyslipidemia-2026_sec-9-2_scenario_q01 | A 55-year-old man with hyperlipidemia is already on simvastatin and is now prescribed diltiazem for hypertension. What is the recommended action for managing his statin therapy? | scenario | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-9-2",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-9",
"sec-9-2"
],
"title_path": [
"Complications of Management",
"Statin-Cardiovascular Drug Interactions"
],
"chapter_id": "sec-9",
"subtopic_id": "sec-9-2",
"char_count": 6790
} |
dyslipidemia-2026_sec-9-2_sdm_q01 | When discussing the initiation of statin therapy with a patient who is currently taking multiple cardiovascular medications, how should I explain the importance of reviewing for potential drug interactions to minimize adverse events? | sdm | dyslipidemia-2026 | 2026 ACC/AHA Guideline on the Management of Dyslipidemia | {
"node_id": "sec-9-2",
"level": 3,
"section_type": "subsection",
"path": [
"bodymatter",
"sec-9",
"sec-9-2"
],
"title_path": [
"Complications of Management",
"Statin-Cardiovascular Drug Interactions"
],
"chapter_id": "sec-9",
"subtopic_id": "sec-9-2",
"char_count": 6790
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.